Immunic (IMUX) Income towards Parent Company (2013 - 2026)

Immunic (IMUX) has 14 years of Income towards Parent Company data on file, last reported at -$35.8 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 34.31% year-over-year to -$35.8 million; the trailing twelve-month figure through Mar 2026 stood at -$112.7 million (down 11.08% YoY), and the FY2025 full-year result was -$222.1 million, down 4.87% from the prior year.
• Income towards Parent Company fell to -$35.8 million in Q1 2026, from -$23.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$19.9 million in Q3 2022 to a low of -$129.7 million in Q4 2022.
• A 5-year average of -$31.2 million and a median of -$25.2 million in 2024 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company tumbled 61.05% in 2022 and jumped 81.61% in 2023, its largest moves.
• Tracing IMUX's Income towards Parent Company over 5 years: stood at -$129.7 million in 2022, then jumped by 81.61% to -$23.9 million in 2023, then slipped by 5.81% to -$25.2 million in 2024, then gained by 7.54% to -$23.3 million in 2025, then plunged by 53.43% to -$35.8 million in 2026.
• Business Quant data shows IMUX's Income towards Parent Company at -$35.8 million in Q1 2026, -$23.3 million in Q4 2025, and -$26.6 million in Q3 2025.